Patents by Inventor Ravi Kaul
Ravi Kaul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11913954Abstract: Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.Type: GrantFiled: February 8, 2021Date of Patent: February 27, 2024Assignee: Bio-Rad Laboratories, Inc.Inventors: Ravi Kaul, Weiming Zheng, Roger Walker
-
Patent number: 11740240Abstract: The present invention relates to the development of novel immunoassays for the detection of neutralizing antibodies and/or high avidity neutralizing antibodies to SARS-CoV-2 spike protein variants or fragments thereof and, optionally, one or more cytokine in patient samples. Novel multiplex and singleplex immunoassays for the detection of neutralizing antibodies and/or high avidity neutralizing antibodies to SARS-CoV-2 spike protein variants or fragments thereof and, optionally, one or more cytokine in patient samples are also provided.Type: GrantFiled: July 19, 2021Date of Patent: August 29, 2023Assignee: BIO-RAD LABORATORIES, INC.Inventors: Qian Gao, Ravi Kaul, Shuxia Zhou, Roger P. Walker
-
Publication number: 20220326240Abstract: The present disclosure relates to the development of novel immunoassays for the detection of SARS-CoV-2 or secreted spike protein (or fragments thereof) in saliva, nasal mucosal sample, throat samples, or nasopharyngeal samples.Type: ApplicationFiled: April 8, 2022Publication date: October 13, 2022Inventors: RAVI KAUL, SHUXIA ZHOU, ROGER P. WALKER
-
Publication number: 20220137047Abstract: The present invention relates to an immunoassay for the detection of Borrelia specific IgG, IgM and IgG/IgM antibodies in biological samples suspected of Lyme infection. The immunoassay can be performed via a standard immunoassay format or on an automated platform. In various embodiments, the immunoassay uses one or more Borrelia specific chimeric peptides VlsE-FlaB (designated pFlaB-mV), VlsE-ErpP (designated pErp59-mV), VlsE-P35 (designated pP35-mV) alone or in combination with one or more outer surface protein C (Osp C) types B or I, p58 and DbpA. Other aspects of the invention provide antigen/substrate combinations and compositions comprising combinations of the disclosed peptides and/or proteins for use in the immunoassays described herein.Type: ApplicationFiled: December 27, 2021Publication date: May 5, 2022Inventors: MICHELLE DELANOY, JOHN FLANAGAN, AUDREY ARJOMANDI, RAVI KAUL, STEVEN R. BINDER
-
Publication number: 20220018838Abstract: The present invention relates to the development of novel immunoassays for the detection of neutralizing antibodies and/or high avidity neutralizing antibodies to SARS-CoV-2 spike protein variants or fragments thereof and, optionally, one or more cytokine in patient samples. Novel multiplex and singleplex immunoassays for the detection of neutralizing antibodies and/or high avidity neutralizing antibodies to SARS-CoV-2 spike protein variants or fragments thereof and, optionally, one or more cytokine in patient samples are also provided.Type: ApplicationFiled: July 19, 2021Publication date: January 20, 2022Inventors: QIAN GAO, RAVI KAUL, SHUXIA ZHOU, ROGER P. WALKER
-
Patent number: 11209431Abstract: The present invention relates to an immunoassay for the detection of Borrelia specific IgG, IgM and IgG/IgM antibodies in biological samples suspected of Lyme infection. The immunoassay can be performed via a standard immunoassay format or on an automated platform. In various embodiments, the immunoassay uses one or more Borrelia specific chimeric peptides VlsE-FlaB (designated pFlaB-mV), VlsE-ErpP (designated pErp59-mV), VlsE-P35 (designated pP35-mV) alone or in combination with one or more outer surface protein C (Osp C) types B or I, p58 and DbpA. Other aspects of the invention provide antigen/substrate combinations and compositions comprising combinations of the disclosed peptides and/or proteins for use in the immunoassays described herein.Type: GrantFiled: October 6, 2016Date of Patent: December 28, 2021Assignee: BIO-RAD LABORATORIES, INC.Inventors: Michelle Delanoy, John Flanagan, Audrey Arjomandi, Ravi Kaul, Steven R. Binder
-
Publication number: 20210156859Abstract: Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.Type: ApplicationFiled: February 8, 2021Publication date: May 27, 2021Inventors: Ravi Kaul, Weiming Zheng, Roger Walker
-
Patent number: 10942182Abstract: Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.Type: GrantFiled: March 27, 2020Date of Patent: March 9, 2021Assignee: Bio-Rad Laboratories, Inc.Inventors: Ravi Kaul, Weiming Zheng, Roger Walker
-
Publication number: 20200225230Abstract: Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.Type: ApplicationFiled: March 27, 2020Publication date: July 16, 2020Inventors: Ravi Kaul, Weiming Zheng, Roger Walker
-
Patent number: 10648981Abstract: Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.Type: GrantFiled: May 7, 2019Date of Patent: May 12, 2020Assignee: Bio-Rad Laboratories, Inc.Inventors: Ravi Kaul, Weiming Zheng, Roger Walker
-
Publication number: 20190265240Abstract: Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.Type: ApplicationFiled: May 7, 2019Publication date: August 29, 2019Inventors: Ravi Kaul, Weiming Zheng, Roger Walker
-
Patent number: 10324091Abstract: Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.Type: GrantFiled: September 11, 2017Date of Patent: June 18, 2019Assignee: Bio-Rad Laboratories, Inc.Inventors: Ravi Kaul, Weiming Zheng, Roger Walker
-
Publication number: 20190025303Abstract: The present invention relates to an immunoassay for the detection of Borrelia specific IgG, IgM and IgG/IgM antibodies in biological samples suspected of Lyme infection. The immunoassay can be performed via a standard immunoassay format or on an automated platform. In various embodiments, the immunoassay uses one or more Borrelia specific chimeric peptides VlsE-FlaB (designated pFlaB-mV), VlsE-ErpP (designated pErp59-mV), VlsE-P35 (designated pP35-mV) alone or in combination with one or more outer surface protein C (Osp C) types B or I, p58 and DbpA. Other aspects of the invention provide antigen/substrate combinations and compositions comprising combinations of the disclosed peptides and/or proteins for use in the immunoassays described herein.Type: ApplicationFiled: October 6, 2016Publication date: January 24, 2019Inventors: MICHELLE DELANOY, JOHN FLANAGAN, AUDREY ARJOMANDI, RAVI KAUL, STEVEN R. BINDER
-
Patent number: 10067135Abstract: Provided herein are multiplex assays for determining whether an individual is or has been infected with Hepatitis B virus, and the stage of infection or resolution. In addition, the multiplex system can discriminate between vaccinated subjects and subjects susceptible to Hepatitis B infection.Type: GrantFiled: February 14, 2018Date of Patent: September 4, 2018Assignee: Bio-Rad Laboratories, Inc.Inventors: Ravi Kaul, Weiming Zheng, Roger Walker
-
Publication number: 20180172687Abstract: Provided herein are multiplex assays for determining whether an individual is or has been infected with Hepatitis B virus, and the stage of infection or resolution. In addition, the multiplex system can discriminate between vaccinated subjects and subjects susceptible to Hepatitis B infection.Type: ApplicationFiled: February 14, 2018Publication date: June 21, 2018Inventors: Ravi Kaul, Weiming Zheng, Roger Walker
-
Patent number: 9927439Abstract: Provided herein are multiplex assays for determining whether an individual is or has been infected with Hepatitis B virus, and the stage of infection or resolution. In addition, the multiplex system can discriminate between vaccinated subjects and subjects susceptible to Hepatitis B infection.Type: GrantFiled: April 25, 2014Date of Patent: March 27, 2018Assignee: Bio-Rad Laboratories, Inc.Inventors: Ravi Kaul, Weiming Zheng, Roger Walker
-
Publication number: 20170370931Abstract: Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.Type: ApplicationFiled: September 11, 2017Publication date: December 28, 2017Inventors: Ravi Kaul, Weiming Zheng, Roger Walker
-
Publication number: 20140323332Abstract: Provided herein are multiplex assays for determining whether an individual is or has been infected with Hepatitis B virus, and the stage of infection or resolution. In addition, the multiplex system can discriminate between vaccinated subjects and subjects susceptible to Hepatitis B infection.Type: ApplicationFiled: April 25, 2014Publication date: October 30, 2014Applicant: Bio-Rad Laboratories, Inc.Inventors: Ravi Kaul, Weiming Zheng, Roger Walker